Litcius/Paper detail

Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India

Inderpaul S Sehgal, Sahajal Dhooria, Valliappan Muthu, Kuruswamy T Prasad, Ashutosh N Aggarwal, Arunaloke Chakrabarti, Hansraj Choudhary, Mandeep Garg, Ritesh Agarwal

2022The Lancet Infectious Diseases67 citationsDOI

Topics & Concepts

MedicineItraconazoleRandomized controlled trialInternal medicineClinical trialSurgeryOral administrationAdverse effectPlacebo-controlled studyIntention-to-treat analysisAntifungal resistance and susceptibilityInfectious Diseases and MycologyFungal Infections and Studies
Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India | Litcius